Title:
癌治療
Document Type and Number:
Japanese Patent JP2013526582
Kind Code:
A
Abstract:
A cell-based vaccine prolongs the survival of cancer patients. The vaccine includes a dose of irradiated cultured lung adenocarcinoma cells (AD100) transfected with HLA A1 and gp96-Ig (human gp96 wherein the endoplasmic reticulum retention signal, KDEL, is replaced with the Fc-portion of human IgG1 and was injected intradermally into patients suffering from advanced, relapsed, or metastatic NSCLC. Administration of the vaccine increased the mean survival time of the patients compared to that of similar patients treated with placebo. Moreover, the immune response of patients to the vaccine (antigen-induced interferon gamma production by T cells) correlated with the survival times.
Inventors:
Podak, Eckhart, Earl.
Application Number:
JP2013511383A
Publication Date:
June 24, 2013
Filing Date:
May 20, 2011
Export Citation:
Assignee:
UNIVERSITY OF MIAMI
International Classes:
A61K39/00; A61P11/00; A61P35/00
Foreign References:
| WO2005030136A2 | 2005-04-07 | |||
| WO2009114085A2 | 2009-09-17 |
Other References:
JPN6015016224; Ｊｏｕｒｎａｌ ｏｆ Ｔｈｏｒａｃｉｃ Ｏｎｃｏｌｏｇｙ ２（８）, 2007, Ｓ１９７-８
JPN6015016225; Ｂｒ Ｊ Ｃａｎｃｅｒ ５５（５）, 1987, ５１３-６
JPN6015016225; Ｂｒ Ｊ Ｃａｎｃｅｒ ５５（５）, 1987, ５１３-６
Attorney, Agent or Firm:
Patent business corporation Kita Aoyama International